Literature DB >> 25702706

Lomitapide.

Sebastiaan C Goulooze1, Adam F Cohen1,2, Robert Rissmann1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25702706      PMCID： PMC4541964          DOI： 10.1111/bcp.12612

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  2 in total

Review 1.  Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

Authors:  Daniel J Rader; John J P Kastelein
Journal:  Circulation       Date:  2014-03-04       Impact factor: 29.690

Review 2.  Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.

Authors:  Frederick J Raal; Raul D Santos
Journal:  Atherosclerosis       Date:  2012-02-16       Impact factor: 5.162
  2 in total
  5 in total

1.  The microsomal triglyceride transfer protein inhibitor lomitapide improves vascular function in mice with obesity.

Authors:  Undral Munkhsaikhan; Youngin Kwon; Amal M Sahyoun; Karima Ait-Aissa; Adam Kassan; Modar Kassan
Journal:  Obesity (Silver Spring)       Date:  2022-03-06       Impact factor: 5.002

Review 2.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

Review 3.  Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy.

Authors:  Isabella Giacomini; Federico Gianfanti; Maria Andrea Desbats; Genny Orso; Massimiliano Berretta; Tommaso Prayer-Galetti; Eugenio Ragazzi; Veronica Cocetta
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 4.  Current Options and Future Perspectives in the Treatment of Dyslipidemia.

Authors:  Saverio Muscoli; Mihaela Ifrim; Massimo Russo; Francesco Candido; Angela Sanseviero; Marialucia Milite; Marco Di Luozzo; Massimo Marchei; Giuseppe Massimo Sangiorgi
Journal:  J Clin Med       Date:  2022-08-12       Impact factor: 4.964

5.  Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites.

Authors:  Ana Carolina C de Sousa; Keletso Maepa; Jill M Combrinck; Timothy J Egan
Journal:  Molecules       Date:  2020-03-29       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.